{"id":"long-acting-beta2-agonist","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nervousness"},{"rate":"1-5","effect":"Palpitations"},{"rate":"1-5","effect":"Muscle cramps"},{"rate":"1-5","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Beta2-agonists activate beta2-adrenergic receptors, which increase intracellular cAMP levels and promote smooth muscle relaxation in the airways. Long-acting formulations provide sustained bronchodilation for 12-24 hours, making them suitable for maintenance therapy in chronic respiratory conditions. They are typically used in combination with inhaled corticosteroids for optimal asthma and COPD control.","oneSentence":"Long-acting beta2-agonists bind to beta2-adrenergic receptors on airway smooth muscle, causing prolonged relaxation and bronchodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:21.206Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT05935332","phase":"PHASE2","title":"Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma","status":"TERMINATED","sponsor":"RAPT Therapeutics, Inc.","startDate":"2023-07-05","conditions":"Asthma","enrollment":38},{"nctId":"NCT07073950","phase":"PHASE4","title":"A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Chronic Obstructive Pulmonary Disease, Hyperinflation","enrollment":56},{"nctId":"NCT07315555","phase":"NA","title":"Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-01-01","conditions":"Community Acquired Pneumonia","enrollment":90},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT06340581","phase":"PHASE1","title":"A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2024-10-17","conditions":"Healthy","enrollment":""},{"nctId":"NCT06721247","phase":"PHASE2, PHASE3","title":"Oral Intake of Mg in Controlled Asthmatic Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2024-11-02","conditions":"Bronchial Asthma","enrollment":166},{"nctId":"NCT06297668","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT06772454","phase":"","title":"To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)","status":"RECRUITING","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2023-01-01","conditions":"Lung Cancer Squamous Cell, COPD","enrollment":60},{"nctId":"NCT03639051","phase":"NA","title":"Evaluation of the Safety and Efficacy of TLD in Patients with COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nuvaira, Inc.","startDate":"2019-05-23","conditions":"COPD","enrollment":464},{"nctId":"NCT06657066","phase":"PHASE2, PHASE3","title":"EFFECTIVENESS of PROBIOTICS in ADULTS with MODERATE to SEVERE PERSISTENT ASTHMA","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2021-12-06","conditions":"Asthma Patients","enrollment":74},{"nctId":"NCT00545844","phase":"PHASE4","title":"Singulair(R) In Asthma And Allergic Rhinitis (0476-383)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04-01","conditions":"Asthma","enrollment":313},{"nctId":"NCT03954132","phase":"","title":"Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-06-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":469},{"nctId":"NCT03654508","phase":"NA","title":"Pharmacogenetics Use For Further Treatment Improvement in childreN","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2018-06-12","conditions":"Asthma in Children","enrollment":102},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT05927155","phase":"PHASE3","title":"Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD","status":"COMPLETED","sponsor":"Erasme University Hospital","startDate":"2021-06-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":30},{"nctId":"NCT00521222","phase":"NA","title":"Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-06","conditions":"Asthma","enrollment":90},{"nctId":"NCT05651958","phase":"NA","title":"Effects of Pranayama Breathing Technique in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2022-02-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT04876677","phase":"PHASE3","title":"Functional Respiratory Imaging Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-05-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25},{"nctId":"NCT04206761","phase":"PHASE3","title":"Investigating the Effects of QVM149 on MRI Ventilation Defects","status":"WITHDRAWN","sponsor":"Dr. Grace Parraga","startDate":"2021-12-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT05145894","phase":"","title":"Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device","status":"UNKNOWN","sponsor":"Healthy Networks","startDate":"2021-09-30","conditions":"Asthma, COPD","enrollment":200},{"nctId":"NCT03627858","phase":"","title":"Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting","status":"COMPLETED","sponsor":"Chiesi SA/NV","startDate":"2018-08-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":149},{"nctId":"NCT04138758","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"COPD","enrollment":42953},{"nctId":"NCT04184297","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":27190},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT03219255","phase":"","title":"RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-08-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1047},{"nctId":"NCT03478657","phase":"PHASE4","title":"An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-18","conditions":"Asthma","enrollment":222},{"nctId":"NCT02147015","phase":"NA","title":"Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2014-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":248},{"nctId":"NCT04271839","phase":"PHASE4","title":"Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients","status":"WITHDRAWN","sponsor":"Mundipharma Pharmaceuticals S.L.","startDate":"2020-06-11","conditions":"Persistent Asthma","enrollment":""},{"nctId":"NCT04199598","phase":"PHASE1","title":"Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-01-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25},{"nctId":"NCT03565302","phase":"NA","title":"Beta2-adrenergic Agonism and Muscle Remodelling","status":"UNKNOWN","sponsor":"Morten Hostrup, PhD","startDate":"2018-06-25","conditions":"Hypertrophy, Physiologic Hypertrophy, Physical Activity","enrollment":72},{"nctId":"NCT03269318","phase":"PHASE4","title":"PRISTINE - Personalised Approach to Improve aSThma prescrIbing iN childrEn","status":"TERMINATED","sponsor":"Brighton and Sussex University Hospitals NHS Trust","startDate":"2017-07-01","conditions":"Asthma","enrollment":2},{"nctId":"NCT03724877","phase":"","title":"Effectiveness of Triple Therapy in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-11-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":8853},{"nctId":"NCT04137029","phase":"NA","title":"Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers","status":"UNKNOWN","sponsor":"Federal State Budgetary Institution, Pulmonology Scientific Research Institute","startDate":"2019-04-24","conditions":"Health, Subjective, Hyperreactivity, Bronchial","enrollment":20},{"nctId":"NCT01706198","phase":"PHASE3","title":"An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-01","conditions":"Asthma","enrollment":4233},{"nctId":"NCT02301975","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-01","conditions":"Asthma","enrollment":1526},{"nctId":"NCT02045875","phase":"PHASE4","title":"Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence","status":"COMPLETED","sponsor":"Asthma Management Systems","startDate":"2014-03-04","conditions":"Asthma","enrollment":50},{"nctId":"NCT01018186","phase":"PHASE3","title":"Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-19","conditions":"Asthma","enrollment":503},{"nctId":"NCT02757209","phase":"NA","title":"Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD","status":"COMPLETED","sponsor":"Consorzio Futuro in Ricerca","startDate":"2016-04","conditions":"Asthma, COPD","enrollment":84},{"nctId":"NCT01086384","phase":"PHASE3","title":"Asthma Exacerbation Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-22","conditions":"Asthma","enrollment":2020},{"nctId":"NCT02105974","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1621},{"nctId":"NCT02152605","phase":"PHASE3","title":"A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":498},{"nctId":"NCT01627327","phase":"PHASE3","title":"Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":623},{"nctId":"NCT01957163","phase":"PHASE3","title":"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":619},{"nctId":"NCT01110200","phase":"PHASE4","title":"Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":639},{"nctId":"NCT01039675","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":51},{"nctId":"NCT02576626","phase":"PHASE4","title":"Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD","status":"COMPLETED","sponsor":"Wouter H. van Geffen","startDate":"2015-12","conditions":"COPD","enrollment":40},{"nctId":"NCT01491802","phase":"PHASE3","title":"Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD","status":"COMPLETED","sponsor":"Queen's University","startDate":"2012-01","conditions":"COPD","enrollment":17},{"nctId":"NCT00964249","phase":"PHASE1","title":"Phase I Study of GW642444M in Healthy Japanese Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":32},{"nctId":"NCT01691547","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":44},{"nctId":"NCT00783003","phase":"PHASE1","title":"A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT00976144","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT01772368","phase":"PHASE2","title":"Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Asthma","enrollment":72},{"nctId":"NCT01312961","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-03","conditions":"Asthma","enrollment":104},{"nctId":"NCT00595361","phase":"NA","title":"How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT02119286","phase":"PHASE3","title":"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":620},{"nctId":"NCT01498679","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01","conditions":"Asthma","enrollment":311},{"nctId":"NCT02837380","phase":"PHASE1","title":"A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT01192178","phase":"PHASE4","title":"Fall Epidemic Viral Pediatric Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Asthma","enrollment":339},{"nctId":"NCT01192191","phase":"PHASE3","title":"A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":187},{"nctId":"NCT01244984","phase":"PHASE3","title":"A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07","conditions":"Asthma","enrollment":243},{"nctId":"NCT02790047","phase":"NA","title":"Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2016-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":50},{"nctId":"NCT00272506","phase":"PHASE3","title":"Pediatric Asthma Controller Trial (PACT)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2002-08","conditions":"Asthma, Lung Diseases","enrollment":""},{"nctId":"NCT01697696","phase":"PHASE3","title":"Long Term Safety Study of NVA237 vs QAB149 in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":511},{"nctId":"NCT01355991","phase":"PHASE1","title":"Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI","status":"UNKNOWN","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2011-08","conditions":"Spinal Cord Injury","enrollment":40},{"nctId":"NCT02547558","phase":"PHASE4","title":"Pulmonary Gas Exchange Response to Indacaterol in COPD","status":"UNKNOWN","sponsor":"Hospital Clinic of Barcelona","startDate":"2015-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":20},{"nctId":"NCT02546349","phase":"PHASE4","title":"Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2014-07","conditions":"COPD","enrollment":143},{"nctId":"NCT01218009","phase":"PHASE3","title":"A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-10","conditions":"Asthma","enrollment":331},{"nctId":"NCT01224964","phase":"NA","title":"Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3","status":"TERMINATED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2011-01","conditions":"Asthmatic Patients","enrollment":1},{"nctId":"NCT01232894","phase":"PHASE3","title":"12-week Open-label Evaluation of Efficacy and Safety of Indacaterol","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":90},{"nctId":"NCT01242098","phase":"","title":"Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2008-01","conditions":"Asthma","enrollment":137},{"nctId":"NCT00463567","phase":"PHASE2, PHASE3","title":"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive","enrollment":2059},{"nctId":"NCT00567476","phase":"PHASE4","title":"Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Asthma","enrollment":116},{"nctId":"NCT00633919","phase":"PHASE2, PHASE3","title":"Efficacy of SLITone in House Dust Mite Allergic Patients","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2006-07","conditions":"Allergy","enrollment":124},{"nctId":"NCT00950794","phase":"PHASE4","title":"Study of Salmeterol (SN408D) for Adult Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09","conditions":"Asthma, Bronchial Asthma","enrollment":367},{"nctId":"NCT00158847","phase":"PHASE4","title":"Modification Of Disease Outcome In COPD","status":"TERMINATED","sponsor":"Leiden University Medical Center","startDate":"2000-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":872,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"long-acting beta2-agonist","genericName":"long-acting beta2-agonist","companyName":"National Heart, Lung, and Blood Institute (NHLBI)","companyId":"national-heart-lung-and-blood-institute-nhlbi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Long-acting beta2-agonists bind to beta2-adrenergic receptors on airway smooth muscle, causing prolonged relaxation and bronchodilation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}